Tags

Type your tag names separated by a space and hit enter

Myo-inositol vs. D-chiro inositol in PCOS treatment.
Minerva Ginecol 2015; 67(4):321-5MG

Abstract

AIM

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women in fertile age. It is an endocrine and metabolic disorder characterized by oligo-anovulation, hyperandrogenism and insulin-resistance. Various therapeutic approaches have been attempted in PCOS, including diet and the use of pharmacological agents such as oral contraceptives (OCs) or anti-androgens. Recently, the introduction of inositol in the treatment plan has proved to be as reasonable as useful in countering the endocrine-metabolic disorders of this syndrome.

METHODS

The aim of our study was to compare the clinical, endocrine and metabolic response after 6 months of therapy in 137 PCOS women characterized by oligomenorrhea and/or acne and/or mild hirsutism and insulin-resistance. The patients were treated with myo-inositol or with D-chiro-inositol or with placebo.

RESULTS

Our study showed that both myo-inositol (MI-PG) and D-chiro inositol (DCI-PG) treatments are able to significantly improve the regularity of the menstrual cycle, the Acne Score, the endocrine and metabolic parameters and the insulin-resistence in young, overweight, PCOS patients.

CONCLUSION

Definitely, we assumed that both treatments with myo-inositol and with D-chiro inositol could be proposed as a potential valid therapeutic approach for the treatment of patients with PCOS. Additionally, further examination and for a longer period of treatment are needed.

Authors+Show Affiliations

Institute of Obstetric and Gynecological Pathology, Santo Bambino Hospital - clara.formuso@gmail.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

25670222

Citation

Formuso, C, et al. "Myo-inositol Vs. D-chiro Inositol in PCOS Treatment." Minerva Ginecologica, vol. 67, no. 4, 2015, pp. 321-5.
Formuso C, Stracquadanio M, Ciotta L. Myo-inositol vs. D-chiro inositol in PCOS treatment. Minerva Ginecol. 2015;67(4):321-5.
Formuso, C., Stracquadanio, M., & Ciotta, L. (2015). Myo-inositol vs. D-chiro inositol in PCOS treatment. Minerva Ginecologica, 67(4), pp. 321-5.
Formuso C, Stracquadanio M, Ciotta L. Myo-inositol Vs. D-chiro Inositol in PCOS Treatment. Minerva Ginecol. 2015;67(4):321-5. PubMed PMID: 25670222.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Myo-inositol vs. D-chiro inositol in PCOS treatment. AU - Formuso,C, AU - Stracquadanio,M, AU - Ciotta,L, Y1 - 2015/02/11/ PY - 2015/2/12/entrez PY - 2015/2/12/pubmed PY - 2016/12/15/medline SP - 321 EP - 5 JF - Minerva ginecologica JO - Minerva Ginecol VL - 67 IS - 4 N2 - AIM: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women in fertile age. It is an endocrine and metabolic disorder characterized by oligo-anovulation, hyperandrogenism and insulin-resistance. Various therapeutic approaches have been attempted in PCOS, including diet and the use of pharmacological agents such as oral contraceptives (OCs) or anti-androgens. Recently, the introduction of inositol in the treatment plan has proved to be as reasonable as useful in countering the endocrine-metabolic disorders of this syndrome. METHODS: The aim of our study was to compare the clinical, endocrine and metabolic response after 6 months of therapy in 137 PCOS women characterized by oligomenorrhea and/or acne and/or mild hirsutism and insulin-resistance. The patients were treated with myo-inositol or with D-chiro-inositol or with placebo. RESULTS: Our study showed that both myo-inositol (MI-PG) and D-chiro inositol (DCI-PG) treatments are able to significantly improve the regularity of the menstrual cycle, the Acne Score, the endocrine and metabolic parameters and the insulin-resistence in young, overweight, PCOS patients. CONCLUSION: Definitely, we assumed that both treatments with myo-inositol and with D-chiro inositol could be proposed as a potential valid therapeutic approach for the treatment of patients with PCOS. Additionally, further examination and for a longer period of treatment are needed. SN - 1827-1650 UR - https://www.unboundmedicine.com/medline/citation/25670222/Myo_inositol_vs__D_chiro_inositol_in_PCOS_treatment_ L2 - http://www.minervamedica.it/index2.t?show=R09Y9999N00A150011 DB - PRIME DP - Unbound Medicine ER -